hyperCORE International, a leading collaborative network of clinical trial sites across North America, has announced significant updates to its executive leadership team. Jeffrey Smyth, President and Executive Director of partner site network TrueBlue Clinical Research, has been appointed Vice President, while Olivia McIver, Director of Clinical Operations of partner site network Applied Research Center, was appointed Treasurer. These strategic appointments strengthen the organization's governance structure and ensure continued alignment with hyperCORE's mission of driving efficiency and excellence across its collective partner site networks.
The importance of these leadership additions extends beyond organizational structure to the broader clinical research landscape. As hyperCORE operates a network of independently operated clinical trial sites that participate in harmonized operational frameworks, strong executive leadership is crucial for maintaining standardization and efficiency across the entire network. This matters because clinical trial efficiency directly impacts how quickly new medical treatments can reach patients who need them.
In their new roles, Smyth and McIver bring complementary expertise to support hyperCORE's continued growth and will play key roles in overseeing financial stewardship and supporting long-term sustainability. The appointments come at a critical time for clinical research, where networks like hyperCORE are increasingly important for conducting large-scale studies efficiently. With over 80 active trial sites across five countries and two continents, hyperCORE's partners have jointly completed more than 7,500 studies involving over 150,000 randomized participants.
Nicholas Focil, President of hyperCORE, emphasized the strategic importance of these appointments. "hyperCORE's strength lies in its ability to unify best-in-class research sites through shared operational excellence," Focil stated. "As we continue to grow, having a dedicated and strategic Vice President and integrated board Treasurer is essential to guide our leadership framework and maintain our strategic mobility across our industry."
The implications of these leadership changes extend to the entire clinical research ecosystem. For pharmaceutical companies and research sponsors, strong governance at hyperCORE means more reliable and efficient trial execution across multiple sites. For patients participating in clinical trials, it translates to more standardized care and potentially faster access to innovative treatments. The network's partner sites include AGA Clinical Trials, Alcanza Clinical Research, Apex Trials, Applied Research Center, Atlas Clinical Research, CaRe Clinics, Epic Medical Research, FOMAT Medical Research, TrueBlue Clinical Research, and QCR Network.
Alongside these new appointments, Nicholas Focil, CEO of FOMAT Medical Research, will continue serving as President, and Mark Scullion, CEO of Atlas Clinical Research, will continue in his role as Secretary. This continuity in leadership positions hyperCORE for its next phase of growth while maintaining the operational frameworks that have made the network successful. The organization remains committed to advancing clinical research through safe, ethical, timely studies, efficient enrollment, and superior retention, empowered by its members' top-tier awards for performance, quality, and innovation.
